COMP <GO>
KNSA vs ABBV // FORWARD P/E MULTIPLE
Kiniksa Pharmaceuticals International plc Class A (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: KNSA 7
— ABBV 8
▲ FORWARD P/E MULTIPLE LEADER: KNSA
LAST: $92.24 (-5.45%) • MKT CAP: $7.67B
forward-pe
109.1x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KNSA VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KNSA | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.50% | 70.20% | +18.30 | KNSA | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 29.00% | -19.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 33.3x | +61.70 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 1.78% | 3.47% | -1.69 | ABBV | /fcf-yield <GO> |
| Operating Margin | 11.40% | 24.60% | -13.20 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 8.70% | 6.90% | +1.80 | KNSA | /net-margins <GO> |
| Revenue Growth (YoY) | 60.10% | 8.60% | +51.50 | KNSA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 24.45 | 5.33 | +19.12 | KNSA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | KNSA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 7.40% | -0.10 | KNSA | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.0 | 72.8 | -9.80 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.11 | 1.15 | -0.04 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 109.1x | 113.1x | -4.00 | KNSA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.67B | $513.86B | -$506.19B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KNSA REV | ABBV REV | KNSA GROSS % | ABBV GROSS % | KNSA FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $677.6M | $61.16B | 88.5% | 70.2% | $136.4M | $17.82B |
| FY 2024 | $423.2M | $56.33B | 85.6% | 70.0% | $25.4M | $17.83B |
| FY 2023 | $270.3M | $54.32B | 44.0% | 44.0% | $1.1M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KNSA // BETA 1.11
ABBV // BETA 1.15